Table 2.

Summary of patient characteristics experiencing monoclonal antibody-induced subacute cutaneous lupus erythematosus

Trait	Percentage	Further detail	Monoclonal antibody	No. of SCLE cases
Age, years (n = 52)	Median 61 Mean 58.9	IQR 51–66 Range 28–82	Etanercept Adalimumab Infliximab Nivolumab Pembrolizumab Golimumab Bevacizumab Abatacept Rituximab Denosumab Efalizumab Natalizumab Ranibizumab Secukinumab Ixekizumab Atezolizumab Ustekinumab	10 6 6 6 6 4 2 2 2 1 1 1 1 1 1 1 1
Sex	73% female	38/52
Ethnicity	94% White 3% Omani 3% Brazilian	27/33 1/3 1/33
Onset time, weeks (n = 47)	Median 9 Mean 13.8	IQR 3–17 Range 1–100
Cessation time, weeks (n = 33)	Median 8 Mean 14	IQR 3–17 Range 2–52
Lesion distribution (n = 44)	68% trunk 64% arms 41% face 30% neck 30% legs 30% back 18% hands 14% head	30/44 trunk 28/44 arms 18/44 face 13/44 neck 13/44 legs 13/44 back 8/44 hands 6/44 head
			First-line treatment (n = 49)
Serology	85% ANA +  62% anti-Ro +  27% anti-dsDNA 42% anti-histone	39/46 24/39 9/33 5/12	Monotherapy: Biologic cessation TOP corticosteroid only PO corticosteroid only DMARD only	16% (8/49) 31% (15/49) 10% (5/49) 8% (4/49)
Haematological	Pancytopenia Lymphopenia Leukopenia Low complement	2/52 3/52 4/52 4/52	Polytherapy: TOP + PO corticosteroid DMARD + PO corticosteroid DMARD + TOP corticosteroid DMARD + PO + TOP corticosteroid Other	6% (3/49) 8% (4/49) 2% (1/49) 10% (5/49) 8% (4/49)

ANA antinuclear antibodies, PO per oral, TOP topical, DMARD disease-modifying antirheumatic drug, IQR interquartile range, SCLE subacute cutaneous lupus erythematosus, dsDNA double-stranded DNA